Scientists reprogram immune cells to hunt cervical cancer
NCT ID NCT05357027
Summary
This early-phase trial tested a personalized cell therapy for advanced cervical cancer that had stopped responding to standard treatments. Researchers collected immune cells from patients, genetically engineered them to recognize and attack cancer cells infected with HPV16, and then reinfused them. The study aimed to determine if this approach was safe and showed any signs of effectiveness, but it was terminated after enrolling only 5 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xiaochun Cheng
Chongqing, Chongqing Municipality, 400000, China
Conditions
Explore the condition pages connected to this study.